{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:51:28Z","timestamp":1794631888783,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41591-025-03958-3","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:09:14Z","timestamp":1757340554000},"page":"4097-4108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses"],"prefix":"10.1038","volume":"31","author":[{"given":"Joshua E.","family":"Reuss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2071-839X","authenticated-orcid":false,"given":"Paul K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza J.","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4672-1981","authenticated-orcid":false,"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suqi","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Niknafs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Wehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4684-8221","authenticated-orcid":false,"given":"Ezgi","family":"Oner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Hosseini-Nami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Battafarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell K.","family":"Hales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Sepesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8040-5205","authenticated-orcid":false,"given":"Julie S.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2952-1830","authenticated-orcid":false,"given":"Tricia","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8273-4395","authenticated-orcid":false,"given":"Janis","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Illei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-8930","authenticated-orcid":false,"given":"Kellie N.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6215-1013","authenticated-orcid":false,"given":"Drew M.","family":"Pardoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-3047","authenticated-orcid":false,"given":"Valsamo","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-6344","authenticated-orcid":false,"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"3958_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","volume":"18","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J. Thorac. Oncol. 18, 792\u2013802 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"3958_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386 (2021).","journal-title":"Lancet"},{"key":"3958_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann. Oncol. 33, 488\u2013499 (2022).","journal-title":"Ann. Oncol."},{"key":"3958_CR4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","volume":"402","author":"Q Chu","year":"2023","unstructured":"Chu, Q. et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet 402, 2295\u20132306 (2023).","journal-title":"Lancet"},{"key":"3958_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","volume":"27","author":"M de Perrot","year":"2009","unstructured":"de Perrot, M. et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27, 1413\u20131418 (2009).","journal-title":"J. Clin. Oncol."},{"key":"3958_CR6","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","volume":"27","author":"LM Krug","year":"2009","unstructured":"Krug, L. M. et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27, 3007\u20133013 (2009).","journal-title":"J. Clin. Oncol."},{"key":"3958_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure, T. et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 12, 763\u2013772 (2011).","journal-title":"Lancet Oncol."},{"key":"3958_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","volume":"12","author":"E Lim","year":"2024","unstructured":"Lim, E. et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir. Med. 12, 457\u2013466 (2024).","journal-title":"Lancet Respir. Med."},{"key":"3958_CR9","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone, T. et al. Perioperative nivolumab in resectable lung cancer. N. Engl. J. Med. 390, 1756\u20131769 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3958_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee, H. et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N. Engl. J. Med. 389, 491\u2013503 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3958_CR11","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3958_CR12","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach, J. V. et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N. Engl. J. Med. 389, 1672\u20131684 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3958_CR13","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.lungcan.2005.03.008","volume":"49","author":"P Van Schil","year":"2005","unstructured":"Van Schil, P. Malignant pleural mesothelioma: staging systems. Lung Cancer 49, S45\u2013S48 (2005).","journal-title":"Lung Cancer"},{"key":"3958_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"3958_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2005.12.013","volume":"52","author":"GR Oxnard","year":"2006","unstructured":"Oxnard, G. R., Armato, S. G. III & Kindler, H. L. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 52, 141\u2013148 (2006).","journal-title":"Lung Cancer"},{"key":"3958_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne, M. J. & Nowak, A. K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 15, 257\u2013260 (2004).","journal-title":"Ann. Oncol."},{"key":"3958_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","volume":"13","author":"SG Armato III","year":"2018","unstructured":"Armato, S. G. III & Nowak, A. K. Revised Modified Response Evaluation Criteria in Solid Tumors for assessment of response in malignant pleural mesothelioma (version 1.1). J. Thorac. Oncol. 13, 1012\u20131021 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"3958_CR18","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","volume":"29","author":"V Anagnostou","year":"2023","unstructured":"Anagnostou, V. et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat. Med. 29, 2559\u20132569 (2023).","journal-title":"Nat. Med."},{"key":"3958_CR19","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","volume":"79","author":"V Anagnostou","year":"2019","unstructured":"Anagnostou, V. et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 79, 1214\u20131225 (2019).","journal-title":"Cancer Res."},{"key":"3958_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly, R. J. et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat. Med. 30, 1023\u20131034 (2024).","journal-title":"Nat. Med."},{"key":"3958_CR21","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial. Cancer Discov. 13, 2394\u20132411 (2023).","journal-title":"Cancer Discov."},{"key":"3958_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1158\/2159-8290.CD-24-0037","volume":"14","author":"V Anagnostou","year":"2024","unstructured":"Anagnostou, V. & Velculescu, V. E. Pushing the boundaries of liquid biopsies for early precision intervention. Cancer Discov. 14, 615\u2013619 (2024).","journal-title":"Cancer Discov."},{"key":"3958_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-481114","volume":"45","author":"JV Aredo","year":"2025","unstructured":"Aredo, J. V. et al. Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring. Am. Soc. Clin. Oncol. Educ. Book 45, e481114 (2025).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3958_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"3958_CR25","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/1878-0261.13803","volume":"19","author":"A Frydendahl","year":"2025","unstructured":"Frydendahl, A. et al. Whole-genome sequencing of cell-free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas. Mol. Oncol. 19, 984\u2013993 (2025).","journal-title":"Mol. Oncol."},{"key":"3958_CR26","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2024.42.16_suppl.8003","volume":"42","author":"M Offin","year":"2024","unstructured":"Offin, M. et al. Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: results of a prospective pilot study. J. Clin. Oncol. 42, 8003\u20138003 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3958_CR27","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3958_CR28","doi-asserted-by":"publisher","unstructured":"Forde, P. M. et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2502931 (2025).","DOI":"10.1056\/NEJMoa2502931"},{"key":"3958_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian, Y. Y. et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N. Engl. J. Med. 393, 217\u2013230 (2025).","journal-title":"N. Engl. J. Med."},{"key":"3958_CR30","doi-asserted-by":"publisher","first-page":"TPS8602","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8602","volume":"41","author":"AS Mansfield","year":"2023","unstructured":"Mansfield, A. S. et al. Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101). J. Clin. Oncol. 41, TPS8602 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3958_CR31","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-24-1883","volume":"30","author":"AW Wyatt","year":"2024","unstructured":"Wyatt, A. W. et al. Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST Working Group. Clin. Cancer Res. 30, 5034\u20135041 (2024).","journal-title":"Clin. Cancer Res."},{"key":"3958_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1200\/JCO-24-02425","volume":"43","author":"HL Kindler","year":"2025","unstructured":"Kindler, H. L. et al. Treatment of pleural mesothelioma: ASCO guideline update. J. Clin. Oncol. 43, 1006\u20131038 (2025).","journal-title":"J. Clin. Oncol."},{"key":"3958_CR33","doi-asserted-by":"publisher","first-page":"S1300","DOI":"10.1016\/j.annonc.2023.10.055","volume":"34","author":"M Reck","year":"2023","unstructured":"Reck, M. et al. LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Ann. Oncol. 34, S1300 (2023).","journal-title":"Ann. Oncol."},{"key":"3958_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","volume":"31","author":"JRM Black","year":"2025","unstructured":"Black, J. R. M. et al. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nat. Med. 31, 70\u201376 (2025).","journal-title":"Nat. Med."},{"key":"3958_CR35","volume":"5","author":"K Parikh","year":"2024","unstructured":"Parikh, K. et al. Individualized cell-free DNA monitoring with chromosomal junctions for mesothelioma. JTO Clin. Res. Rep. 5, 100692 (2024).","journal-title":"JTO Clin. Res. Rep."},{"key":"3958_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2018.07.028","volume":"124","author":"M Hylebos","year":"2018","unstructured":"Hylebos, M. et al. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients. Lung Cancer 124, 19\u201322 (2018).","journal-title":"Lung Cancer"},{"key":"3958_CR37","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/COC.0000000000000745","volume":"43","author":"N Alpert","year":"2020","unstructured":"Alpert, N., van Gerwen, M., Flores, R. & Taioli, E. Gender differences in outcomes of patients with mesothelioma. Am. J. Clin. Oncol. 43, 792\u2013797 (2020).","journal-title":"Am. J. Clin. Oncol."},{"key":"3958_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21798-w","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat. Commun. 12, 1751 (2021).","journal-title":"Nat. Commun."},{"key":"3958_CR39","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.1158\/1538-7445.AM2024-6559","volume":"84","author":"C Alarcon","year":"2024","unstructured":"Alarcon, C. et al. Abstract 6559: Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: the PROVENC3 study. Cancer Res. 84, 6559 (2024).","journal-title":"Cancer Res."},{"key":"3958_CR40","doi-asserted-by":"publisher","unstructured":"Georgiadis, A. et al. Abstract ST135: Detecting molecular residual disease through integrated tumor tissue, germline, and plasma whole genome sequencing analyses. Association for Molecular Pathology 2023 Annual Meeting Abstracts. J. Mol. Diagn. https:\/\/doi.org\/10.1016\/S1525-1578(23)00249-0 (2023).","DOI":"10.1016\/S1525-1578(23)00249-0"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03958-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03958-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03958-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:59:33Z","timestamp":1765814373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03958-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3958"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03958-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.E.R. receives research funding to his institution from Genentech\/Roche, Verastem, Nuvalent, Arcus, Revolution Medicines, Regeneron, Amgen, DualityBio and AstraZeneca and serves in a consultant\/advisory role for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Seagen, Gilead, Janssen, Novocure, Regeneron, Summit Therapeutics, Pfizer, Eli Lilly, Natera, Merck, EMD Serono, Roche Diagnostics and OncoHost. C.H. serves in a consultant\/advisory role for Belay Diagnostics and Johnson & Johnson. N.N. is an inventor on patent application 17\/598,690 submitted by Johns Hopkins University related to genomic features of response to immunotherapy. M.S. is employed by and owns stock in Labcorp. J.S.D. receives research funding to the institution from Bristol Myers Squibb and is a consultant for NextPoint Therapeutics. J.T. has participated on advisory boards for AstraZeneca, Bristol Myers Squibb, Merck, Regeneron, Elephas, Lunaphore, Roche and Moderna and has received research grants from Bristol Myers Squibb and Akoya Biosciences. T.R.C. reports research funding received by the institution from Janssen; receiving honoraria from AstraZeneca, the Society for Immunotherapy of Cancer and TotalCME; and being named on a patent for a machine learning algorithm for immune-related pathologic response criteria. P.B.I. reports consulting\/advisory board membership for AstraZeneca, Bristol Myers Squibb, Roche, Sanofi, AbbVie, Merus and Agilent. K.N.S. has received honoraria from Adaptive Biotechnologies and Illumina; has received research support from AbbVie, Bristol Myers Squibb and AstraZeneca; holds several patents related to the MANAFEST technology and TCR discovery; and is a scientific founder of Clasp Therapeutics. D.M.P. holds equity in Aduro Biotech, DNAtrix, Ervaxx, Five Prime Therapeutics, Immunomic, Potenza and Trieza Therapeutics. D.M.P. is a member of scientific advisory boards for Bristol Myers Squibb, Camden Nexus II, Five Prime Therapeutics and WindMIL. D.M.P. is a member of the board of directors for Dracen Pharmaceuticals. A.S.T. receives research funding to the institution from Ariad, Bristol Myers Squibb, Eli Lilly, Genentech, Millennium, Polaris, AstraZeneca, Boehringer Ingelheim, Epizyme, Merck, Novartis and Seattle Genetics and receives consulting fees from Ariad, Bristol Myers Squibb, Eli Lilly, Genentech, Merck, Pfizer, Seattle Genetics, AstraZeneca, Boehringer Ingelheim, EMD Serono, GlaxoSmithKline, Novartis and Roche. J.R.B. receives research funding to Johns Hopkins University from AstraZeneca and Bristol Myers Squibb; serves in a consultant\/advisory role for AstraZeneca, RAPT Therapeutics, Mestag, GlaxoSmithKline, Amgen, Sanofi Aventis, Summit Therapeutics, Genentech and Bayer; and is on the Data Safety and Monitoring Board (DSMB) for Genmab. P.M.F. has received research funding (directly to the institution) from AstraZeneca, Bristol Myers Squibb, Novartis, Regeneron, Kyowa and BioNTech; has served in a consultant\/advisory role for AstraZeneca, AbbVie, Amgen, Ascendis, BioNTech, Bristol Myers Squibb, ChromaCode, Daiichi Sankyo, F-Star, Genelux, Gilead, iTeos, Novartis, Novocure, Regeneron, Tavotek, Teva, Genentech, Sanofi, Surface, Janssen, G1 and Merck; and has served on DSMBs for Polaris and Flame. V.A. receives research funding to Johns Hopkins University from AstraZeneca and Personal Genome Diagnostics; has received research funding to Johns Hopkins University from Bristol Myers Squibb and Delfi Diagnostics in the past 5\u2009years; is an advisory board member for AstraZeneca and NeoGenomics (compensated); and receives honoraria from Foundation Medicine, Guardant Health, Roche and Personal Genome Diagnostics. These arrangements have been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. V.A. is an inventor on patent applications (63\/276,525, 17\/779,936, 16\/312,152, 16\/341,862, 17\/047,006 and 17\/598,690) submitted by Johns Hopkins University related to cancer genomic analyses, ctDNA therapeutic response monitoring and immunogenomic features of response to immunotherapy that have been licensed to one or more entities. Under the terms of these license agreements, the university and inventors are entitled to fees and royalty distributions. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}